Back to Authors

Miller, Bruce L.

https://orcid.org/0000-0002-2152-4220

A5046120768 | I180670191

Mayo Clinic

University of California, San Francisco

Citations 127

Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts

Neurology Neuroimmunology & Neuroinflammation | October 29, 2016 | Volume: 3 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000301 | PMID 27844039

Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease

Alzheimer's & Dementia | March 15, 2016 | Volume: 12 | Issue: 8 | Pages: 862-871

10.1016/j.jalz.2016.01.010 | PMID 26993346

AbstractIntroductionThe genetics underlying posterior cortical atrophy (PCA), typically a rare variant of Alzheimer's disease (AD), remain uncertain.MethodsWe genotyped 302 PCA patients from 11 centers, calculated risk at 24 loci for AD/DLB and performed an exploratory genome‐wide association study.ResultsWe confirm that variation in/near APOE/TOMM40 (P = 6 × 10−14) alters PCA risk, but with smaller effect than for typical AD (PCA: odds ratio [OR] = 2.03, typical AD: OR = 2.83, P = .0007). We found evidence for risk in/near CR1 (P = 7 × 10−4), ABCA7 (P = .02) and BIN1 (P = .04). ORs at variants near INPP5D and NME8 did not overlap between PCA and typical AD. Exploratory genome‐wide association studies confirmed APOE and identified three novel loci: rs76854344 near CNTNAP5 (P = 8 × 10−10 OR = 1.9 [1.5–2.3]); rs72907046 near FAM46A (P = 1 × 10−9 OR = 3.2 [2.1–4.9]); and rs2525776 near SEMA3C (P = 1 × 10−8, OR = 3.3 [2.1–5.1]).DiscussionWe provide evidence for genetic risk factors specifically related to PCA. We identify three candidate loci that, if replicated, may provide insights into selective vulnerability and phenotypic diversity in AD.
P3‐309: Advancing research and treatment of frontotemporal lobar degeneration (ARTFL): Preparing for clinical trials for ftld in north america

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_16 | Pages: No page available

10.1016/j.jalz.2015.06.1683

O5‐03‐01: Longitudinal evaluation of familial frontotemporal dementia subjects (LEFFTDS): Subject characteristics, aims, and methodology

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2015.07.457

P2‐079: Neuronal origin plasma exosomes provide novel biomarkers for lysosomal dysfunction in Alzheimer's disease

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_11 | Pages: No page available

10.1016/j.jalz.2015.06.616

Association of traumatic brain injury with subsequent neurological and psychiatric disease: a meta-analysis

Journal of Neurosurgery | August 28, 2015 | Volume: 124 | Issue: 2 | Pages: 511-526

10.3171/2015.2.jns14503 | PMID 26315003

OBJECT Mild traumatic brain injury (TBI) has been proposed as a risk factor for the development of Alzheimer’s disease, Parkinson’s disease, depression, and other illnesses. This study’s objective was to determine the association of prior mild TBI with the subsequent diagnosis (that is, at least 1 year postinjury) of neurological or psychiatric disease. METHODS All studies from January 1995 to February 2012 reporting TBI as a risk factor for diagnoses of interest were identified by searching PubMed, study references, and review articles. Reviewers abstracted the data and assessed study designs and characteristics. RESULTS Fifty-seven studies met the inclusion criteria. A random effects meta-analysis revealed a significant association of prior TBI with subsequent neurological and psychiatric diagnoses. The pooled odds ratio (OR) for the development of any illness subsequent to prior TBI was 1.67 (95% CI 1.44–1.93, p < 0.0001). Prior TBI was independently associated with both neurological (OR 1.55, 95% CI 1.31–1.83, p < 0.0001) and psychiatric (OR 2.00, 95% CI 1.50–2.66, p < 0.0001) outcomes. Analyses of individual diagnoses revealed higher odds of Alzheimer’s disease, Parkinson’s disease, mild cognitive impairment, depression, mixed affective disorders, and bipolar disorder in individuals with previous TBI as compared to those without TBI. This association was present when examining only studies of mild TBI and when considering the influence of study design and characteristics. Analysis of a subset of studies demonstrated no evidence that multiple TBIs were associated with higher odds of disease than a single TBI. CONCLUSIONS History of TBI, including mild TBI, is associated with the development of neurological and psychiatric illness. This finding indicates that either TBI is a risk factor for heterogeneous pathological processes or that TBI may contribute to a common pathological mechanism.
Memory, executive, and multidomain subtle cognitive impairment

Neurology | June 18, 2015 | Volume: 85 | Issue: 2 | Pages: 144-153

10.1212/wnl.0000000000001738 | PMID 26085606

Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease

Neurology | June 11, 2015 | Volume: 85 | Issue: 1 | Pages: 40-47

10.1212/wnl.0000000000001702 | PMID 26062630

Low neural exosomal levels of cellular survival factors in Alzheimer's disease

Annals of Clinical and Translational Neurology | May 13, 2015 | Volume: 2 | Issue: 7 | Pages: 769-773

10.1002/acn3.211 | PMID 26273689

AbstractTranscription factors that mediate neuronal defenses against diverse stresses were quantified in plasma neural‐derived exosomes of Alzheimer's disease or frontotemporal dementia patients and matched controls. Exosomal levels of low‐density lipoprotein receptor‐related protein 6, heat‐shock factor‐1, and repressor element 1‐silencing transcription factor all were significantly lower in Alzheimer's disease patients than controls (P < 0.0001). In frontotemporal dementia, the only significant difference was higher levels of repressor element 1‐silencing transcription factor than in controls. Exosomal transcription factors were diminished 2–10 years before clinical diagnosis of Alzheimer's disease. Low exosomal levels of survival proteins may explain decreased neuronal resistance to Alzheimer's disease neurotoxic proteins.
Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures

Neurology | January 22, 2015 | Volume: 84 | Issue: 7 | Pages: 729-737

10.1212/wnl.0000000000001231 | PMID 25609767